Short-term skeletal changes in children with newly diagnosed glucocorticoid-treated nephrotic syndrome
Leanne M. Ward(Children's Hospital of Eastern Ontario), Francis H. Glorieux(Shriners Hospitals for Children - Canada), Helen Nadel(Helios Klinikum Emil von Behring), Frank Rauch(Montreal Children's Hospital), Brian C. Lentle(University of British Columbia), Nathalie Alos(Centre Hospitalier Universitaire Sainte-Justine), David Stephure(University of Calgary), Stephanie A. Atkinson(McMaster University), Johannes Roth, Robert Stein(Cleveland Clinic), Celia Rodd, Ai Ni(Children's Hospital of Eastern Ontario), Nazih Shenouda, Kerry Siminoski, Elizabeth Cummings(Dalhousie University), John Hay(Brock University), Päivi Miettunen(Alberta Children's Hospital), Mary Ann Matzinger, Robert Couch(University of Alberta), Shayne Taback(Children's Hospital Research Institute of Manitoba)
Cited by 0
Related Papers
Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis
|New England Journal of Medicine|1997|694
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465
Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients
|Arthritis & Rheumatology|2014|430
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419